What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Two pivotal Phase 3 RCTs showed statistically significant improvement in ADHD core symptoms for both centanafadine doses compared to placebo. However, no head-to-head trials versus active ADHD medications are available, and indirect comparisons suggest centanafadine’s efficacy may be lower than a stimulant.
Does the economic case hold at the expected price? — Cost effectiveness
No economic analyses, cost-utility models, or ICER estimates are available for centanafadine.
Is there quality-of-life evidence payers weigh? — Quality of life
No published results using generic QoL instruments were found, and no utility weights or QALY calculations for centanafadine use were identified.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Common AEs include headache and decreased appetite, with serious AEs occurring in 1.8% of patients. Indirect data suggest centanafadine generally has fewer AEs than stimulants or atomoxetine.
Was the drug compared against what payers expect? — Comparator Selection
The trials used placebo as the comparator, which does not reflect active standard of care (stimulant or atomoxetine therapy). No head-to-head data against standard treatments.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is well-defined, but generalizability beyond the study demographics is uncertain. No formal subgroup outcomes were reported.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Centanafadine fits standard diagnostic criteria and would be prescribed by clinicians experienced in adult ADHD, consistent with standards of care.
Are the wider system costs understood? — Resource Use and Cost Implications
No data on centanafadine’s price, dosing costs, or impact on healthcare utilization were found.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The core evidence comes from multiple industry-sponsored Phase 3 RCTs. Internal validity for efficacy vs placebo is high, but lack of published full reports is a limitation.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
No formal sensitivity analyses or uncertainty quantification are available. Key areas of uncertainty include the true effect size in broader populations and long-term benefit durability.
